Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide

Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide

Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the...

Full description

Bibliographic Details
Main Authors: Muhammad Mustafa Abeer, Anand Kumar Meka, Naisarg Pujara, Tushar Kumeria, Ekaterina Strounina, Rute Nunes, Ana Costa, Bruno Sarmento, Sumaira Z. Hasnain, Benjamin P. Ross, Amirali Popat
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Pharmaceutics
Subjects:
large pore silica nanoparticles
exenatide
oral delivery
anti-diabetic peptides
Online Access:https://www.mdpi.com/1999-4923/11/8/418

Internet

https://www.mdpi.com/1999-4923/11/8/418

Similar Items